Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety
June 16, 2015 16:10 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces First Quarter 2015 Financial Results
May 04, 2015 16:10 ET | Aegerion Pharmaceuticals, Inc.
- Company records $59.4 million in total net product sales - - JUXTAPID® net product sales of $57.3 million in the first quarter of 2015 represents 112% growth over the first quarter of 2014...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Observes Rare Disease Day
February 28, 2015 07:15 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results
February 26, 2015 16:10 ET | Aegerion Pharmaceuticals, Inc.
- Company records $158.4 million in net product sales of JUXTAPID® in 2014, representing 226% growth over 2013 - - Company generates $17.9 million in positive cash flow from operations in the...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company Healthcare Conference
February 25, 2015 16:10 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
April 09, 2014 08:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules Approved in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
February 10, 2014 08:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
January 20, 2014 08:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 20, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results
March 06, 2013 07:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results
January 06, 2012 12:57 ET | Aegerion Pharmaceuticals, Inc.
Efficacy and Safety Profile Maintained Company to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Aegerion...